



Autolus Therapeutics PLC 2025 Annual General Meeting Results

On June 26, 2025, Autolus Therapeutics PLC (the “Company”) held its 2025 annual general meeting of shareholders (the “AGM”).

At the AGM, the holders of 220,382,576 votes of the Company’s ordinary shares, which may be represented by American Depositary Shares (“ADSs”), were represented in person or by proxy, constituting a quorum.

Voting at the AGM was conducted by way of a poll, and each ordinary share, which may be represented by ADSs, issued and outstanding as of the close of business on the record date was entitled to one (1) vote on each resolution at the AGM.

The following are the voting results for the proposals considered and voted upon at the AGM, each of which was an ordinary resolution requiring a simple majority:

Proposal	For	Against	Vote Withheld
Resolution 1: To receive and adopt the Company’s accounts for the financial year ended 31 December 2024 and the associated reports of the Directors and auditors (the “2024 Annual Report and Accounts”).	219,809,664	97,503	477,332
Resolution 2: To approve the Directors’ remuneration report (excluding the Directors’ remuneration policy), as set out in the 2024 Annual Report and Accounts.	216,036,710	4,285,817	61,972
Resolution 3: To approve the Directors’ remuneration policy contained in the 2024 Annual Report and Accounts, which take effect immediately after the end of the AGM.	203,397,251	16,925,364	61,884
Resolution 4: To re-appoint Ernst & Young LLP as auditors of the Company to hold office from the conclusion of the 2025 AGM until the conclusion of the 2026 AGM and to authorise the Directors to determine the auditors’ remuneration.	220,272,345	110,231	1,923
Resolution 5: To re-elect Dr. R Iannone as a Director.	199,402,000	20,750,286	232,213

Proposal	For	Against	Vote Withheld
Resolution 6: To re-elect Dr. R Rao as a Director.	219,956,853	194,729	232,917
Resolution 7: To approve the Autolus Therapeutics plc Employee Share Purchase Plan with Sharesave Sub-Plan adopted by the Board on 20 May 2025 (the "Purchase Plan"), with 3,000,000 (three million) Shares (as defined therein) available for issuance under the Purchase Plan, and with the directors authorised to do all acts and things as are or may be necessary or expedient to carry the same into effect, notwithstanding that the directors may be interested in the same.	219,651,874	706,780	25,845

Based on the foregoing votes, the shareholders approved all of the proposals. The results were in line with the recommendations made by the Company's board of directors.